GLSIClinical Trials•globenewswire•
Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences
Sentiment:Positive (65)
Summary
STAFFORD, Texas, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that Noble Capital Markets has initiated company-sponsored equity research coverage on the Company. The full report by Noble Capital Markets Research Analyst Robert LeBoyer is available here:
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 20, 2025 by globenewswire